Mankind Pharma Ltd (MANKIND) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company reported a strong overall revenue growth of 21% year-over-year, largely driven by the consolidation of the BSV business and growth in the base business.
- Domestic business performance was impacted by supply chain disruptions due to the new GST rollout, resulting in secondary sales growth of 6.3%, which was lower than the Indian Pharmaceutical Market (IPM) growth of 7.2%.
- The chronic therapy segment continued its outperformance, with its share of the business increasing by 200 basis points year-over-year to 37.1%, driven by strong performance in cardiac and anti-diabetic portfolios.
- EBITDA margin for the quarter stood at 25%, a decline of 280 basis points year-over-year, primarily attributed to increased R&D expenses, higher employee costs, and a slight dip in gross margin.
- The company has made significant progress in strengthening its balance sheet, reducing its net debt by 488 crores during the quarter and improving the net debt to Adjusted EBITDA ratio to 1.4x from 1.8x as of March 31, 2025.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.